0001209191-20-051048.txt : 20200917 0001209191-20-051048.hdr.sgml : 20200917 20200917192001 ACCESSION NUMBER: 0001209191-20-051048 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200717 FILED AS OF DATE: 20200917 DATE AS OF CHANGE: 20200917 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: THURMAN RANDY H CENTRAL INDEX KEY: 0001204059 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 201182338 MAIL ADDRESS: STREET 1: 222 MERCHANDISE MART PLAZA STREET 2: SUITE 2024 CITY: CHICAGO STATE: IL ZIP: 60654 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 4260 U.S. ROUTE 1 CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 4260 U.S. ROUTE 1 CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2020-07-17 2020-07-21 0 0001649989 Outlook Therapeutics, Inc. OTLK 0001204059 THURMAN RANDY H C/O OUTLOOK THERAPEUTICS, INC. 4260 US ROUTE 1 MONMOUTH JUNCTION NJ 08852 1 0 0 0 Stock Option (Right to Buy) 1.58 2020-07-17 4 A 0 154555 0.00 A 2030-07-17 Common Stock 154555 154555 D The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on July 17, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. This Form 4/A is being filed to reflect the correct number of shares underlying the option granted to the Reporting Person on July 17, 2020 to 154,555 shares instead of the 210,000 shares reported in the Form 4 filed with the Securities and Exchange Commission on July 21, 2020. /s/ Lawrence Kenyon, Attorney-in-Fact 2020-09-17